Immix Biopharma Inc (IMMX) USD0.0001

Sell:$1.56Buy:$1.70$0.07 (4.24%)

Prices delayed by at least 15 minutes
Sell:$1.56
Buy:$1.70
Change:$0.07 (4.24%)
Deal now
Prices delayed by at least 15 minutes
Sell:$1.56
Buy:$1.70
Change:$0.07 (4.24%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.

Key people

Ilya Rachman
Chairman of the Board, Chief Executive Officer
Vladimir Torchilin
Scientific Co-Founder
Gabriel Morris
Chief Financial Officer, Director
Nandan Oza
Head - Chemistry, Manufacturing, and Control
Graham Ross
Acting Chief Medical Officer, Head - Clinical Development
Helen C. Adams
Independent Director
Jane M. Buchan
Independent Director
Yekaterina Chudnovsky
Independent Director
Jason Hsu
Independent Director
Magda Marquet
Independent Director
Click to see more

Key facts

  • EPIC
    IMMX
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US45258H1068
  • Market cap
    $44.63m
  • Employees
    18
  • Shares in issue
    27.79m
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.